Theriva Biologics financials
$0.2100−3.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$24.1M | -$26.3M | -$21.4M | -$21.6M |
| Net income | -$25.2M | -$25.7M | -$18.3M | -$20.0M |
| Net margin | — | — | — | — |
| Diluted EPS | $-2.08 | $-19.03 | $-28.48 | $-32.75 |
| EBITDA | -$23.9M | -$19.3M | -$21.3M | -$21.5M |
| Operating cash flow | -$16.7M | -$16.9M | -$18.3M | -$21.2M |
| Free cash flow | -$16.7M | -$16.9M | -$18.5M | -$21.3M |
| Diluted shares | 12.1M | 1.3M | 0.6M | 0.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $13.1M | $11.6M | $23.2M | $41.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.7M | $153.0K | $225.0K | $278.0K |
| Total assets | $38.2M | $35.4M | $55.2M | $71.9M |
| Total liabilities | $22.9M | $16.3M | $15.5M | $17.3M |
| Shareholders' equity | $15.4M | $19.1M | $37.0M | $51.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology